{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T01:13:35Z","timestamp":1788830015742,"version":"build-2803163510"},"reference-count":445,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:00:00Z","timestamp":1780790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Materials Today Bio"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.mtbio.2026.103334","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T16:07:33Z","timestamp":1780934853000},"page":"103334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Delivering the future of immunotherapy: A state-of-the-art review of gene editing in immune cells with lipid nanoparticles"],"prefix":"10.1016","volume":"39","author":[{"given":"Ivan","family":"Ciganek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0052-5948","authenticated-orcid":false,"given":"Christophe","family":"Delehedde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Galy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Cogn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Rameix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Bordeianu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3161-3937","authenticated-orcid":false,"given":"Chantal","family":"Pichon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mtbio.2026.103334_bib1","doi-asserted-by":"crossref","first-page":"eadd8643","DOI":"10.1126\/science.add8643","article-title":"CRISPR technology: a decade of genome editing is only the beginning","volume":"379","author":"Wang","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.mtbio.2026.103334_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202451008","article-title":"Lipid nanoparticle\u2010mediated RNA delivery for immune cell modulation","author":"Kim","year":"2024","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.mtbio.2026.103334_bib3","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.mtbio.2026.103334_bib4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41578-024-00725-7","article-title":"CRISPR\u2013Cas9 delivery strategies for the modulation of immune and non-immune cells","volume":"10","author":"Alsaiari","year":"2025","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.mtbio.2026.103334_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/science.1258096","article-title":"The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.mtbio.2026.103334_bib6","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","article-title":"Development and applications of CRISPR-Cas9 for genome engineering","volume":"157","author":"Hsu","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.mtbio.2026.103334_bib7","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mtbio.2026.103334_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115359","article-title":"Delivery of nucleic acid based genome editing platforms via lipid nanoparticles: clinical applications","volume":"211","author":"Masarwy","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.mtbio.2026.103334_bib9","article-title":"Viral vectors for the in vivo delivery of CRISPR components: advances and challenges","volume":"10","author":"Mengstie","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib10","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.cell.2022.03.045","article-title":"Therapeutic in vivo delivery of gene editing agents","volume":"185","author":"Raguram","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.mtbio.2026.103334_bib11","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1038\/s41467-021-26714-w","article-title":"Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice","volume":"12","author":"Kenjo","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103334_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2019.11.005","article-title":"Rational designs of in vivo CRISPR-Cas delivery systems","volume":"168","author":"Xu","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.mtbio.2026.103334_bib13","first-page":"1","article-title":"mRNA vaccines in the COVID-19 pandemic and beyond","volume":"73","author":"Hogan","year":"2021","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.mtbio.2026.103334_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102457","article-title":"Advanced delivery systems for gene editing: a comprehensive review from the GenE-HumDi COST action working group","volume":"36","author":"Cavazza","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.mtbio.2026.103334_bib15","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2307800120","article-title":"Endosomal escape: a bottleneck for LNP-mediated therapeutics","volume":"121","author":"Chatterjee","year":"2024","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.mtbio.2026.103334_bib16","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1126\/science.1138140","article-title":"CRISPR provides acquired resistance against viruses in prokaryotes","volume":"315","author":"Barrangou","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.mtbio.2026.103334_bib17","doi-asserted-by":"crossref","first-page":"9275","DOI":"10.1093\/nar\/gkr606","article-title":"The Streptococcus thermophilus CRISPR\/Cas system provides immunity in Escherichia coli","volume":"39","author":"Sapranauskas","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.mtbio.2026.103334_bib18","article-title":"A CRISPR view of the 2020 nobel prize in chemistry","volume":"131","author":"Uyhazi","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.mtbio.2026.103334_bib19","first-page":"1","article-title":"CRISPR\u2013Cas9 structures and mechanisms","volume":"46","author":"Jiang","year":"2015","journal-title":"Annu. Rev. Biophys."},{"key":"10.1016\/j.mtbio.2026.103334_bib20","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable Dual-RNA\u2013Guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.mtbio.2026.103334_bib21","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.mtbio.2026.103334_bib22","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.1232033","article-title":"RNA-guided human genome engineering via Cas9","volume":"339","author":"Mali","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.mtbio.2026.103334_bib23","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","article-title":"ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering","volume":"31","author":"Gaj","year":"2013","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib24","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41392-023-01309-7","article-title":"CRISPR\/Cas9 therapeutics: progress and prospects","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.mtbio.2026.103334_bib25","article-title":"CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients","volume":"6","author":"Su","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mtbio.2026.103334_bib26","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.mtbio.2026.103334_bib27","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1249558","article-title":"CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer","volume":"6","author":"Su","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.mtbio.2026.103334_bib28","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41591-020-0840-5","article-title":"Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer","volume":"26","author":"Lu","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.mtbio.2026.103334_bib29","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1056\/NEJMoa1817426","article-title":"CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia","volume":"381","author":"Xu","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mtbio.2026.103334_bib30","first-page":"309","article-title":"First-in-human phase 1 CRISPR gene editing cancer trials:are we ready?","volume":"17","author":"Baylis","year":"2017","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.mtbio.2026.103334_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41581-022-00636-2","article-title":"Advances in CRISPR therapeutics","volume":"19","author":"Chavez","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.mtbio.2026.103334_bib32","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.4192","article-title":"Repair of double-strand breaks induced by CRISPR\u2013Cas9 leads to large deletions and complex rearrangements","volume":"36","author":"Kosicki","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib33","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nature16526","article-title":"High-fidelity CRISPR\u2013Cas9 nucleases with no detectable genome-wide off-target effects","volume":"529","author":"Kleinstiver","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.mtbio.2026.103334_bib34","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bj.2019.10.005","article-title":"CRISPR-Cas12a: functional overview and applications","volume":"43","author":"Paul","year":"2020","journal-title":"Biomed. J."},{"key":"10.1016\/j.mtbio.2026.103334_bib35","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/s41375-024-02444-y","article-title":"Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy","volume":"38","author":"Lei","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.mtbio.2026.103334_bib36","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.cell.2024.01.035","article-title":"A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells","volume":"187","author":"Tieu","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.mtbio.2026.103334_bib37","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-020-0084-6","article-title":"Base editing: advances and therapeutic opportunities","volume":"19","author":"Porto","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.mtbio.2026.103334_bib38","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1038\/s41467-019-13007-6","article-title":"Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors","volume":"10","author":"Webber","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103334_bib39","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1038\/s41375-021-01282-6","article-title":"Base-edited CAR T cells for combinational therapy against T cell malignancies","volume":"35","author":"Georgiadis","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.mtbio.2026.103334_bib40","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.2022015825","article-title":"Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL","volume":"140","author":"Diorio","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mtbio.2026.103334_bib41","article-title":"Precision enhancement of CAR-NK cells through non-viral engineering and highly multiplexed base editing","volume":"2024","author":"Wang","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.mtbio.2026.103334_bib42","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-edited CAR7 T cells for relapsed T-Cell acute lymphoblastic leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mtbio.2026.103334_bib43","first-page":"1","article-title":"Engineering a photoactivatable A-to-I RNA base editor for gene therapy in vivo","author":"Li","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib44","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41576-022-00541-1","article-title":"Prime editing for precise and highly versatile genome manipulation","volume":"24","author":"Chen","year":"2023","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.mtbio.2026.103334_bib45","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.mtbio.2026.103334_bib46","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.1182\/blood-2023-181869","article-title":"Multiplex prime editing and PASSIGE TM for non-viral generation of an allogeneic CAR-T cell product","volume":"142","author":"Pomeroy","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.mtbio.2026.103334_bib47","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41551-024-01227-1","article-title":"Efficient site-specific integration of large genes in mammalian cells via continuously evolved recombinases and prime editing","volume":"9","author":"Pandey","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.mtbio.2026.103334_bib48","first-page":"1","article-title":"Genome editing with DNA-dependent polymerases","author":"Cowan","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib49","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.tibtech.2020.10.012","article-title":"CRISPR\/Cas-Based epigenome editing: advances, applications, and clinical utility","volume":"39","author":"Goell","year":"2021","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib50","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41556-020-00620-7","article-title":"CRISPR technologies for precise epigenome editing","volume":"23","author":"Nakamura","year":"2021","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.mtbio.2026.103334_bib51","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/2159-8290.CD-22-1350","article-title":"SUV39H1 ablation enhances long-term CAR T function in solid tumors","volume":"14","author":"L\u00f3pez-Cobo","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.mtbio.2026.103334_bib52","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1126\/science.aav4294","article-title":"Programmed DNA destruction by miniature CRISPR-Cas14 enzymes","volume":"362","author":"Harrington","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.mtbio.2026.103334_bib53","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41586-019-0908-x","article-title":"CasX enzymes comprise a distinct family of RNA-guided genome editors","volume":"566","author":"Liu","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.mtbio.2026.103334_bib54","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1126\/science.abb1400","article-title":"CRISPR-Cas\u03a6 from huge phages is a hypercompact genome editor","volume":"369","author":"Pausch","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.mtbio.2026.103334_bib55","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1016\/j.molcel.2021.08.008","article-title":"Engineered miniature CRISPR-cas system for mammalian genome regulation and editing","volume":"81","author":"Xu","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.mtbio.2026.103334_bib56","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/10409238.2016.1237935","article-title":"Sleeping beauty transposition: from biology to applications","volume":"52","author":"Narayanavari","year":"2017","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.mtbio.2026.103334_bib57","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1172\/JCI86721","article-title":"Phase I trials using sleeping beauty to generate CD19-specific CAR T cells","volume":"126","author":"Kebriaei","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.mtbio.2026.103334_bib58","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1016\/j.ymthe.2022.06.006","article-title":"Universal allogeneic CAR T cells engineered with sleeping beauty transposons and CRISPR-CAS9 for cancer immunotherapy","volume":"30","author":"Tipanee","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mtbio.2026.103334_bib59","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41587-022-01574-x","article-title":"Precise cut-and-paste DNA insertion using engineered type V-K CRISPR-associated transposases","volume":"41","author":"Tou","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib60","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41587-023-01748-1","article-title":"Targeted DNA integration in human cells without double-strand breaks using CRISPR-associated transposases","volume":"42","author":"Lampe","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib61","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1038\/s41467-025-57416-2","article-title":"Integration of therapeutic cargo into the human genome with programmable type V-K CAST","volume":"16","author":"Liu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103334_bib62","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1038\/s41467-021-27183-x","article-title":"Find and cut-and-transfer (FiCAT) mammalian genome engineering","volume":"12","author":"Pallar\u00e8s-Masmitj\u00e0","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103334_bib63","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1182\/blood-2024-208968","article-title":"Delivery of gene writers in vivo to hematopoietic stem cells and T cells using targeted and untargeted lipid nanoparticles (LNP)","volume":"144","author":"Monte","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.mtbio.2026.103334_bib64","series-title":"Methods and Compositions for Modulating a Genome","author":"Rosenblum","year":"2021"},{"key":"10.1016\/j.mtbio.2026.103334_bib65","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41586-024-07552-4","article-title":"Bridge RNAs direct programmable recombination of target and donor DNA","volume":"630","author":"Durrant","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.mtbio.2026.103334_bib66","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/crispr.2019.0074","article-title":"Detection and modulation of DNA translocations during multi-gene genome editing in T cells","volume":"3","author":"Bothmer","year":"2020","journal-title":"CRISPR J."},{"key":"10.1016\/j.mtbio.2026.103334_bib67","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41588-021-00838-7","article-title":"Chromothripsis as an on-target consequence of CRISPR\u2013Cas9 genome editing","volume":"53","author":"Leibowitz","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.mtbio.2026.103334_bib68","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/s41591-018-0050-6","article-title":"p53 inhibits CRISPR\u2013Cas9 engineering in human pluripotent stem cells","volume":"24","author":"Ihry","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.mtbio.2026.103334_bib69","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.omtm.2023.06.003","article-title":"The p53 challenge of hematopoietic stem cell gene editing","volume":"30","author":"Dorset","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.mtbio.2026.103334_bib70","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1038\/s41587-024-02488-6","article-title":"Genome editing with the HDR-enhancing DNA-PKcs inhibitor AZD7648 causes large-scale genomic alterations","volume":"43","author":"Cullot","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib71","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2427216122","article-title":"Quadruple adenine base\u2013edited allogeneic CAR T cells outperform CRISPR\/Cas9 nuclease\u2013engineered T cells","volume":"122","author":"Engel","year":"2025","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.mtbio.2026.103334_bib72","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41586-019-1314-0","article-title":"Off-target RNA mutation induced by DNA base editing and its elimination by mutagenesis","volume":"571","author":"Zhou","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.mtbio.2026.103334_bib73","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","article-title":"Identification of preexisting adaptive immunity to Cas9 proteins in humans","volume":"25","author":"Charlesworth","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.mtbio.2026.103334_bib74","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41591-018-0204-6","article-title":"High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population","volume":"25","author":"Wagner","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.mtbio.2026.103334_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.973326","article-title":"Delivering the CRISPR\/Cas9 system for engineering gene therapies: recent cargo and delivery approaches for clinical translation","volume":"10","author":"Foley","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib76","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.tibtech.2018.08.010","article-title":"Non-viral delivery to enable genome editing","volume":"37","author":"Rui","year":"2019","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib77","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1021\/acsnano.7b07874","article-title":"Macrophage-specific in vivo gene editing using cationic lipid-assisted polymeric nanoparticles","volume":"12","author":"Luo","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.mtbio.2026.103334_bib78","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41392-021-00645-w","article-title":"Spatiotemporal control of CRISPR\/Cas9 gene editing","volume":"6","author":"Zhuo","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.mtbio.2026.103334_bib79","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jbiotec.2015.04.024","article-title":"Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection","volume":"208","author":"Liang","year":"2015","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib80","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mtbio.2026.103334_bib81","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"issue":"21","key":"10.1016\/j.mtbio.2026.103334_bib82","article-title":"Revisiting the need for mRNA nucleoside modification in CAR T cell engineering","volume":"1","author":"Kahwaji","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.mtbio.2026.103334_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102263","article-title":"Enhancing natural killer cells proliferation and cytotoxicity using imidazole-based lipid nanoparticles encapsulating interleukin-2 mRNA","volume":"35","author":"Delehedde","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.mtbio.2026.103334_bib84","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/nat.2018.0734","article-title":"MicroRNAs enable mRNA therapeutics to selectively program cancer cells to self-destruct","volume":"28","author":"Jain","year":"2018","journal-title":"nucleic acid Ther"},{"key":"10.1016\/j.mtbio.2026.103334_bib85","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1073\/pnas.0511045103","article-title":"Cell-type-specific signatures of microRNAs on target mRNA expression","volume":"103","author":"Sood","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.mtbio.2026.103334_bib86","doi-asserted-by":"crossref","first-page":"614","DOI":"10.7150\/thno.47007","article-title":"Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR\/Cas9 genome editing","volume":"11","author":"Zhang","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.mtbio.2026.103334_bib87","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nbt.3081","article-title":"Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo","volume":"33","author":"Zuris","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib88","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41423-021-00792-8","article-title":"Protein synthesis, degradation, and energy metabolism in T cell immunity","volume":"19","author":"Marchingo","year":"2022","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.mtbio.2026.103334_bib89","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1084\/jem.20171626","article-title":"Optimized RNP transfection for highly efficient CRISPR\/Cas9-mediated gene knockout in primary T cells","volume":"215","author":"Seki","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.mtbio.2026.103334_bib90","doi-asserted-by":"crossref","first-page":"8998","DOI":"10.1002\/anie.201914575","article-title":"Spatiotemporal control of CRISPR\/Cas9 function in cells and zebrafish using light\u2010activated guide RNA","volume":"59","author":"Zhou","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.mtbio.2026.103334_bib91","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/v11010028","article-title":"Viral delivery systems for CRISPR","volume":"11","author":"Xu","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.mtbio.2026.103334_bib92","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.molcel.2022.02.002","article-title":"Chimeric CRISPR-CasX enzymes and guide RNAs for improved genome editing activity","volume":"82","author":"Tsuchida","year":"2022","journal-title":"Mol. Cell"},{"key":"10.1016\/j.mtbio.2026.103334_bib93","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41408-021-00508-1","article-title":"AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia","volume":"11","author":"Nawaz","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.mtbio.2026.103334_bib94","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.cell.2022.12.022","article-title":"An evolved AAV variant enables efficient genetic engineering of murine T cells","volume":"186","author":"Nyberg","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.mtbio.2026.103334_bib95","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.immuni.2025.01.009","article-title":"In vivo engineering of murine T cells using the evolved adeno-associated virus variant Ark313","volume":"58","author":"Nyberg","year":"2025","journal-title":"Immunity"},{"key":"10.1016\/j.mtbio.2026.103334_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.834002","article-title":"CRISPR gene editing of human primary NK and T cells for cancer immunotherapy","volume":"12","author":"Elmas","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mtbio.2026.103334_bib97","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1089\/hum.2020.049","article-title":"Adeno-associated virus and hematopoietic stem cells: the potential of adeno-associated virus hematopoietic stem cells in genetic medicines","volume":"31","author":"Chatterjee","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.mtbio.2026.103334_bib98","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV vector immunogenicity in humans: a long journey to successful gene transfer","volume":"28","author":"Verdera","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mtbio.2026.103334_bib99","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/s41434-023-00390-5","article-title":"Successes and challenges in clinical gene therapy","volume":"30","author":"Kohn","year":"2023","journal-title":"Gene Ther."},{"key":"10.1016\/j.mtbio.2026.103334_bib100","doi-asserted-by":"crossref","first-page":"11479","DOI":"10.1073\/pnas.0604993103","article-title":"Targeting lentiviral vectors to specific cell types in vivo","volume":"103","author":"Yang","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.mtbio.2026.103334_bib101","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2174\/1566523054546224","article-title":"Altering the tropism of lentiviral vectors through pseudotyping","volume":"5","author":"Cronin","year":"2005","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.mtbio.2026.103334_bib102","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3109\/08923970903420582","article-title":"Lentiviral vectors for immune cells targeting","volume":"32","author":"Froelich","year":"2010","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.mtbio.2026.103334_bib103","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.3389\/fimmu.2019.02873","article-title":"Efficient and robust NK-Cell transduction with Baboon Envelope pseudotyped lentivector","volume":"10","author":"Colamartino","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mtbio.2026.103334_bib104","first-page":"301","article-title":"Innate immunity","volume":"415","author":"Swainson","year":"2008","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.mtbio.2026.103334_bib105","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.mtbio.2026.103334_bib106","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3390\/biomedicines10010107","article-title":"Non-integrating lentiviral vectors in clinical applications: a glance through","volume":"10","author":"Gurumoorthy","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.mtbio.2026.103334_bib107","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3390\/v12101103","article-title":"The old and the new: prospects for non-integrating lentiviral vector technology","volume":"12","author":"Apolonia","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.mtbio.2026.103334_bib108","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3390\/biom10060839","article-title":"Recent advances in CRISPR\/Cas9 delivery strategies","volume":"10","author":"Yip","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.mtbio.2026.103334_bib109","volume":"vol. 8","author":"Johnson","year":"2018"},{"key":"10.1016\/j.mtbio.2026.103334_bib110","first-page":"456","volume":"vol. 26","author":"Hung","year":"2018"},{"key":"10.1016\/j.mtbio.2026.103334_bib111","article-title":"Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV","volume":"2","author":"Kararoudi","year":"2022","journal-title":"Cell Rep. Methods"},{"key":"10.1016\/j.mtbio.2026.103334_bib112","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/nar\/gkaa1251","article-title":"Dynamics and competition of CRISPR\u2013Cas9 ribonucleoproteins and AAV donor-mediated NHEJ, MMEJ and HDR editing","volume":"49","author":"Fu","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.mtbio.2026.103334_bib113","article-title":"Cell death due to electroporation \u2013 a review","volume":"141","author":"Napotnik","year":"2021","journal-title":"Bioelectrochemistry"},{"key":"10.1016\/j.mtbio.2026.103334_bib114","first-page":"4244","volume":"vol. 4","author":"Wilk","year":"2020"},{"key":"10.1016\/j.mtbio.2026.103334_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101139","article-title":"Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering","volume":"31","author":"Kitte","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.mtbio.2026.103334_bib116","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood.2022019333","article-title":"Lipid nanoparticles allow efficient and harmless ex vivo gene editing of human hematopoietic cells","volume":"142","author":"Vavassori","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.mtbio.2026.103334_bib117","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54292-0","article-title":"In vivo gene editing of T-cells in lymph nodes for enhanced cancer immunotherapy","volume":"15","author":"Qu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103334_bib118","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12343","article-title":"Engineering extracellular vesicles to deliver CRISPR ribonucleoprotein for gene editing","volume":"12","author":"Whitley","year":"2023","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.mtbio.2026.103334_bib119","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12057","article-title":"Covalent conjugation of extracellular vesicles with peptides and nanobodies for targeted therapeutic delivery","volume":"10","author":"Pham","year":"2021","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.mtbio.2026.103334_bib120","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.3390\/cancers15102838","article-title":"Surface-engineered extracellular vesicles in cancer immunotherapy","volume":"15","author":"Johnson","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.mtbio.2026.103334_bib121","article-title":"CRISPR delivery with extracellular vesicles: promises and challenges","volume":"2","author":"Berggreen","year":"2023","journal-title":"J. Extracell. Biol."},{"key":"10.1016\/j.mtbio.2026.103334_bib122","doi-asserted-by":"crossref","DOI":"10.3389\/fgeed.2021.604371","article-title":"Baboon envelope pseudotyped \u201cNanoblades\u201d carrying Cas9\/gRNA complexes allow efficient genome editing in human T, B, and CD34+ cells and Knock-in of AAV6-Encoded donor DNA in CD34+ cells","volume":"3","author":"Gutierrez-Guerrero","year":"2021","journal-title":"Front. Genome Ed."},{"key":"10.1016\/j.mtbio.2026.103334_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109207","article-title":"Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering","volume":"35","author":"Hamilton","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.mtbio.2026.103334_bib124","first-page":"1","article-title":"Customizable virus-like particles deliver CRISPR\u2013Cas9 ribonucleoprotein for effective ocular neovascular and Huntington's disease gene therapy","author":"Ling","year":"2025","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib125","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/s41587-023-02085-z","article-title":"In vivo human T cell engineering with enveloped delivery vehicles","volume":"42","author":"Hamilton","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib126","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41551-024-01296-2","article-title":"Safer and efficient base editing and prime editing via ribonucleoproteins delivered through optimized lipid-nanoparticle formulations","volume":"9","author":"Ho\u0142ubowicz","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.mtbio.2026.103334_bib127","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMoa2504747","article-title":"Patient-specific in vivo gene editing to treat a rare genetic disease","volume":"392","author":"Musunuru","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mtbio.2026.103334_bib128","article-title":"Comprehensive analysis of lipid nanoparticle formulation and preparation for RNA delivery","volume":"8","author":"Haque","year":"2024","journal-title":"Int. J. Pharm. X"},{"key":"10.1016\/j.mtbio.2026.103334_bib129","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1021\/acs.molpharmaceut.1c00916","article-title":"Lipid-nanoparticle-based delivery of CRISPR\/Cas9 genome-editing components","volume":"19","author":"Kazemian","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.mtbio.2026.103334_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120826","article-title":"Microfluidic formulation of nanoparticles for biomedical applications","volume":"274","author":"Shepherd","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.mtbio.2026.103334_bib131","doi-asserted-by":"crossref","first-page":"9483","DOI":"10.1038\/s41598-022-13112-5","article-title":"Optimal self-assembly of lipid nanoparticles (LNP) in a ring micromixer","volume":"12","author":"Ripoll","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mtbio.2026.103334_bib132","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jconrel.2022.02.017","article-title":"Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery","volume":"344","author":"Maeki","year":"2022","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103334_bib133","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.mtbio.2026.103334_bib134","first-page":"945","volume":"vol. 13","author":"Delehedde","year":"2021"},{"key":"10.1016\/j.mtbio.2026.103334_bib135","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10213","article-title":"Cytosolic delivery of nucleic acids: the case of ionizable lipid nanoparticles","volume":"6","author":"Schlich","year":"2021","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.mtbio.2026.103334_bib136","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","article-title":"A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human Primates","volume":"26","author":"Sabnis","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mtbio.2026.103334_bib137","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1038\/s41467-022-33157-4","article-title":"Payload distribution and capacity of mRNA lipid nanoparticles","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103334_bib138","article-title":"Lung\u2010specific mRNA delivery by ionizable lipids with defined structure\u2010function relationship and unique protein Corona feature","volume":"12","author":"He","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.mtbio.2026.103334_bib139","article-title":"Lipid nanoparticles for delivery of CRISPR gene editing components","author":"Wu","year":"2025","journal-title":"Small Methods"},{"key":"10.1016\/j.mtbio.2026.103334_bib140","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201902575","article-title":"Fast and efficient CRISPR\/Cas9 genome editing in vivo enabled by bioreducible lipid and messenger RNA nanoparticles","volume":"31","author":"Liu","year":"2019","journal-title":"Adv. Mater."},{"key":"10.1016\/j.mtbio.2026.103334_bib141","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1038\/s41565-024-01765-4","article-title":"Acid-degradable lipid nanoparticles enhance the delivery of mRNA","volume":"19","author":"Zhao","year":"2024","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib142","doi-asserted-by":"crossref","first-page":"7233","DOI":"10.1038\/s41467-021-27493-0","article-title":"An ionizable lipid toolbox for RNA delivery","volume":"12","author":"Han","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103334_bib143","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1038\/s41467-022-32281-5","article-title":"Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo","volume":"13","author":"Ni","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103334_bib144","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1021\/acs.nanolett.1c02503","article-title":"Orthogonal design of experiments for optimization of lipid nanoparticles for mRNA engineering of CAR T cells","volume":"22","author":"Billingsley","year":"2022","journal-title":"Nano Lett."},{"key":"10.1016\/j.mtbio.2026.103334_bib145","first-page":"1578","volume":"vol. 20","author":"Billingsley","year":"2020"},{"key":"10.1016\/j.mtbio.2026.103334_bib146","first-page":"129","volume":"vol. 99","author":"Cheng","year":"2016"},{"key":"10.1016\/j.mtbio.2026.103334_bib147","first-page":"1","volume":"vol. 11","author":"Patel","year":"2020"},{"key":"10.1016\/j.mtbio.2026.103334_bib148","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jconrel.2022.05.020","article-title":"Hydroxycholesterol substitution in ionizable lipid nanoparticles for mRNA delivery to T cells","volume":"347","author":"Patel","year":"2022","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103334_bib149","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202303857","article-title":"Modulating lipid nanoparticles with histidinamide\u2010conjugated cholesterol for improved intracellular delivery of mRNA","volume":"13","author":"Jung","year":"2024","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.mtbio.2026.103334_bib150","first-page":"549","volume":"vol. 10","author":"\u00c1lvarez-Benedicto","year":"2022"},{"key":"10.1016\/j.mtbio.2026.103334_bib151","first-page":"819","volume":"vol. 345","author":"LoPresti","year":"2022"},{"key":"10.1016\/j.mtbio.2026.103334_bib152","first-page":"28","volume":"vol. 99","author":"Suk","year":"2016"},{"key":"10.1016\/j.mtbio.2026.103334_bib153","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jconrel.2022.09.002","article-title":"Stealth nanoparticles in oncology: facing the PEG dilemma","volume":"351","author":"Zalba","year":"2022","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103334_bib154","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3390\/pharmaceutics15020597","article-title":"Effect of PEG anchor and serum on lipid nanoparticles: development of a nanoparticles tracking method","volume":"15","author":"Berger","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.mtbio.2026.103334_bib155","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jconrel.2025.01.071","article-title":"Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines","volume":"380","author":"Zhang","year":"2025","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103334_bib156","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2013.66","article-title":"Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles","volume":"2","author":"Mui","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.mtbio.2026.103334_bib157","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102803","article-title":"Spleen-targeted mRNA delivery via long-chain PEGylated lipids at low molar ratio enhances antitumor immunity against melanoma","volume":"37","author":"Liu","year":"2026","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.mtbio.2026.103334_bib159","first-page":"163","article-title":"Anti-PEG antibodies: properties, formation","volume":"154\u2013155","author":"Kozma","year":"2020","journal-title":"testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals"},{"key":"10.1016\/j.mtbio.2026.103334_bib160","doi-asserted-by":"crossref","first-page":"17","DOI":"10.34133\/bmr.0017","article-title":"Development of lipid nanoparticle formulation for the repeated administration of mRNA therapeutics","volume":"28","author":"Lee","year":"2024","journal-title":"Biomater. Res."},{"key":"10.1016\/j.mtbio.2026.103334_bib161","doi-asserted-by":"crossref","first-page":"10634","DOI":"10.1021\/acsanm.0c01834","article-title":"Polysarcosine-functionalized lipid nanoparticles for therapeutic mRNA delivery","volume":"3","author":"Nogueira","year":"2020","journal-title":"ACS Appl. Nano Mater."},{"key":"10.1016\/j.mtbio.2026.103334_bib162","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.3390\/pharmaceutics15082068","article-title":"Polysarcosine-functionalized mRNA lipid nanoparticles tailored for immunotherapy","volume":"15","author":"Wilhelmy","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.mtbio.2026.103334_bib163","first-page":"86","article-title":"Engineering LNPs with polysarcosine lipids for mRNA delivery","volume":"37","author":"Kang","year":"2024","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.mtbio.2026.103334_bib164","doi-asserted-by":"crossref","first-page":"4908","DOI":"10.1002\/pol.20240154","article-title":"Influence of structural variations in polysarcosine functionalized lipids on lipid nanoparticle\u2010mediated mRNA delivery","volume":"62","author":"Tan","year":"2024","journal-title":"J. Polym. Sci."},{"key":"10.1016\/j.mtbio.2026.103334_bib165","first-page":"313","volume":"vol. 15","author":"Cheng","year":"2020"},{"key":"10.1016\/j.mtbio.2026.103334_bib166","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1021\/acsbiomedchemau.4c00085","article-title":"Exploring the effects of incorporating different bioactive phospholipids into messenger ribonucleic acid lipid nanoparticle (mRNA LNP) formulations","volume":"5","author":"Chen","year":"2025","journal-title":"ACS Bio Med Chem Au"},{"key":"10.1016\/j.mtbio.2026.103334_bib167","doi-asserted-by":"crossref","first-page":"5659","DOI":"10.1038\/s41467-024-50093-7","article-title":"Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation","volume":"15","author":"Su","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103334_bib168","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.omtm.2023.06.005","article-title":"Lipid nanoparticle mRNA systems containing high levels of sphingomyelin engender higher protein expression in hepatic and extra-hepatic tissues","volume":"30","author":"Chander","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.mtbio.2026.103334_bib169","article-title":"Lipid nanoparticles with fine\u2010tuned composition show enhanced Colon targeting as a platform for mRNA therapeutics","volume":"12","author":"Rampado","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.mtbio.2026.103334_bib170","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1038\/s41467-025-58523-w","article-title":"Liposomal lipid nanoparticles for extrahepatic delivery of mRNA","volume":"16","author":"Cheng","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103334_bib171","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1021\/acs.molpharmaceut.2c01024","article-title":"Delivery and expression of mRNA in the secondary lymphoid organs drive immune responses to lipid Nanoparticle-mRNA vaccines after intramuscular injection","volume":"20","author":"Takanashi","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.mtbio.2026.103334_bib172","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/biomedicines12010059","article-title":"Biodistribution of RNA vaccines and of their products: evidence from human and animal studies","volume":"12","author":"Pateev","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.mtbio.2026.103334_bib173","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.ymthe.2025.01.008","article-title":"Visualizing lipid nanoparticle trafficking for mRNA vaccine delivery in non-human primates","volume":"33","author":"Buckley","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mtbio.2026.103334_bib174","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.xphs.2022.12.026","article-title":"Effect of cholesterol content of lipid composition in mRNA-LNPs on the protein expression in the injected site and liver after local administration in mice","volume":"112","author":"Kawaguchi","year":"2023","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.mtbio.2026.103334_bib175","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101402","article-title":"Reducing off-target expression of mRNA therapeutics and vaccines in the liver with microRNA binding sites","volume":"33","author":"Parrett","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.mtbio.2026.103334_bib176","doi-asserted-by":"crossref","first-page":"6709","DOI":"10.1021\/acsnano.0c10064","article-title":"Apolipoprotein E binding drives structural and compositional rearrangement of mRNA-Containing lipid nanoparticles","volume":"15","author":"Sebastiani","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.mtbio.2026.103334_bib177","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1294929","article-title":"Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design","volume":"14","author":"Clemente","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mtbio.2026.103334_bib178","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.804159","article-title":"In vivo motility patterns displayed by immune cells under inflammatory conditions","volume":"12","author":"Pizzagalli","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mtbio.2026.103334_bib179","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.apsb.2024.08.030","article-title":"Optimized lipid nanoparticles enable effective CRISPR\/Cas9-mediated gene editing in dendritic cells for enhanced immunotherapy","volume":"15","author":"Mao","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.mtbio.2026.103334_bib180","doi-asserted-by":"crossref","first-page":"eabe2888","DOI":"10.1126\/sciadv.abe2888","article-title":"Microneedle-assisted genome editing: a transdermal strategy of targeting NLRP3 by CRISPR-Cas9 for synergistic therapy of inflammatory skin disorders","volume":"7","author":"Wan","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.mtbio.2026.103334_bib181","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/17425247.2023.2185220","article-title":"Shaping the future from the small scale: dry powder inhalation of CRISPR-Cas9 lipid nanoparticles for the treatment of lung diseases","volume":"20","author":"Carneiro","year":"2023","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.mtbio.2026.103334_bib182","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.actbio.2024.03.031","article-title":"Immunometabolic reprogramming of macrophages with inhalable CRISPR\/Cas9 nanotherapeutics for acute lung injury intervention","volume":"181","author":"Huang","year":"2024","journal-title":"Acta Biomater."},{"key":"10.1016\/j.mtbio.2026.103334_bib183","doi-asserted-by":"crossref","first-page":"16151","DOI":"10.1021\/acsnano.4c01171","article-title":"High-throughput in vivo screening identifies differential influences on mRNA lipid nanoparticle immune cell delivery by administration route","volume":"18","author":"Hamilton","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.mtbio.2026.103334_bib184","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jconrel.2023.07.058","article-title":"The interplay of quaternary ammonium lipid structure and protein corona on lung-specific mRNA delivery by selective organ targeting (SORT) nanoparticles","volume":"361","author":"Dilliard","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103334_bib185","first-page":"1","article-title":"Dual SORT LNPs for multi-organ base editing","author":"Kim","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib186","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41565-024-01847-3","article-title":"Nature-inspired platform nanotechnology for RNA delivery to myeloid cells and their bone marrow progenitors","volume":"20","author":"Hofstraat","year":"2025","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib187","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1038\/s41467-025-58523-w","article-title":"Liposomal lipid nanoparticles for extrahepatic delivery of mRNA","volume":"16","author":"Cheng","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103334_bib188","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121339","article-title":"In situ T-cell transfection by anti-CD3-conjugated lipid nanoparticles leads to T-cell activation, migration, and phenotypic shift","volume":"281","author":"Kheirolomoom","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.mtbio.2026.103334_bib189","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1016\/j.ymthe.2021.06.004","article-title":"Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs","volume":"29","author":"Tomb\u00e1cz","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mtbio.2026.103334_bib190","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.mtbio.2026.103334_bib191","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.mtbio.2026.103334_bib192","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1021\/acs.nanolett.3c00304","article-title":"In vivo RNA delivery to hematopoietic stem and progenitor cells via targeted lipid nanoparticles","volume":"23","author":"Shi","year":"2023","journal-title":"Nano Lett."},{"key":"10.1016\/j.mtbio.2026.103334_bib193","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1038\/s41467-018-06936-1","article-title":"Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes","volume":"9","author":"Veiga","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103334_bib194","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2314747121","article-title":"Precision treatment of viral pneumonia through macrophage-targeted lipid nanoparticle delivery","volume":"121","author":"Zhao","year":"2024","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.mtbio.2026.103334_bib195","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1021\/acs.molpharmaceut.3c00735","article-title":"Unleashing the potential: designing antibody-targeted lipid nanoparticles for industrial applications with CMC considerations and clinical outlook","volume":"21","author":"Wang","year":"2024","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.mtbio.2026.103334_bib196","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.3389\/fimmu.2017.01287","article-title":"Antibody or antibody fragments: implications for molecular imaging and targeted therapy of solid tumors","volume":"8","author":"Xenaki","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mtbio.2026.103334_bib197","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.molimm.2006.05.009","article-title":"The change of the scFv into the Fab format improves the stability and in vivo toxin neutralization capacity of recombinant antibodies","volume":"44","author":"Quintero-Hern\u00e1ndez","year":"2007","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.mtbio.2026.103334_bib198","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2119\/molmed.2016.00043","article-title":"Use of single-chain antibody derivatives for targeted drug delivery","volume":"22","author":"Safdari","year":"2016","journal-title":"Mol. Med."},{"key":"10.1016\/j.mtbio.2026.103334_bib199","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1039\/C6SC02403C","article-title":"Antibody fragments as nanoparticle targeting ligands: a step in the right direction","volume":"8","author":"Richards","year":"2016","journal-title":"Chem. Sci."},{"key":"10.1016\/j.mtbio.2026.103334_bib200","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1021\/acs.bioconjchem.2c00024","article-title":"Evaluation of cellular targeting by fab' vs full-length antibodies in antibody\u2013nanoparticle conjugates (ANCs) using CD4 T-cells","volume":"33","author":"Singh","year":"2022","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.mtbio.2026.103334_bib201","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/mt.2015.175","article-title":"Delivery of siRNAs to dendritic cells using DEC205-Targeted lipid nanoparticles to inhibit immune responses","volume":"24","author":"Katakowski","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mtbio.2026.103334_bib202","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jconrel.2007.11.005","article-title":"Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, fab' fragments and single chain Fv","volume":"126","author":"Cheng","year":"2008","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103334_bib203","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.yexmp.2010.01.006","article-title":"Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv","volume":"88","author":"Loomis","year":"2010","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.mtbio.2026.103334_bib204","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41565-017-0043-5","article-title":"A modular platform for targeted RNAi therapeutics","volume":"13","author":"Kedmi","year":"2018","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib205","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jconrel.2021.07.034","article-title":"Therapeutic inhibitory RNA in head and neck cancer via functional targeted lipid nanoparticles","volume":"337","author":"Kampel","year":"2021","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103334_bib206","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102520","article-title":"Targeted mRNA delivery with bispecific antibodies that tether LNPs to cell-surface markers","author":"Dietmair","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.mtbio.2026.103334_bib207","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.3390\/ijms24044176","article-title":"Application progress of the single domain antibody in medicine","volume":"24","author":"Tang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mtbio.2026.103334_bib208","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124254","article-title":"Nanobody-liposomes as novel cancer vaccine platform to efficiently stimulate T cell immunity","volume":"660","author":"Bouma","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.mtbio.2026.103334_bib209","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.1158\/1538-7445.AM2025-6119","article-title":"Abstract 6119: efficient generation of active CAR-T cells from healthy donors and lymphoma patients","volume":"85","author":"Sawyer","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.mtbio.2026.103334_bib210","article-title":"A versatile antibody capture system that drives precise in vivo delivery of mRNA loaded lipid nanoparticles and enhances gene expression","volume":"2024.08.07","author":"Chen","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.mtbio.2026.103334_bib211","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejpb.2013.05.006","article-title":"Formulation of pH responsive peptides as inhalable dry powders for pulmonary delivery of nucleic acids","volume":"86","author":"Liang","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.mtbio.2026.103334_bib212","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.3390\/pharmaceutics15061648","article-title":"Targeting peptides: the new generation of targeted drug delivery systems","volume":"15","author":"Todaro","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.mtbio.2026.103334_bib213","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3390\/pharmaceutics15061603","article-title":"Increased bone marrow uptake and accumulation of very-late Antigen-4 targeted lipid nanoparticles","volume":"15","author":"Swart","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.mtbio.2026.103334_bib214","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3390\/pharmaceutics15020602","article-title":"Liposomal formulations of a polyleucine\u2013antigen conjugate as therapeutic vaccines against cervical cancer","volume":"15","author":"Firdaus","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.mtbio.2026.103334_bib215","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jconrel.2020.08.023","article-title":"DP7-C-modified liposomes enhance immune responses and the antitumor effect of a neoantigen-based mRNA vaccine","volume":"328","author":"Zhang","year":"2020","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103334_bib216","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1208\/s12248-012-9329-6","article-title":"Design and characterization of novel peptide-coated lipid nanoparticles for targeting Anti-HIV drug to CD4 expressing cells","volume":"14","author":"Endsley","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.mtbio.2026.103334_bib217","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2025.03.018","article-title":"CD47 peptide-cloaked lipid nanoparticles promote cell-specific mRNA delivery","author":"Papp","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mtbio.2026.103334_bib218","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.nano.2018.01.009","article-title":"Selective liposome targeting of folate receptor positive immune cells in inflammatory diseases","volume":"14","author":"Poh","year":"2018","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.mtbio.2026.103334_bib219","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202318515","article-title":"Development of mannosylated lipid nanoparticles for mRNA cancer vaccine with high antigen presentation efficiency and immunomodulatory capability","volume":"63","author":"Lei","year":"2024","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.mtbio.2026.103334_bib220","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.ymthe.2024.02.028","article-title":"SMART-lipid nanoparticles enabled mRNA vaccine elicits cross-reactive humoral responses against the omicron sub-variants","volume":"32","author":"Mahalingam","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mtbio.2026.103334_bib221","volume":"vol. 487","author":"Gao","year":"2020"},{"key":"10.1016\/j.mtbio.2026.103334_bib222","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123531","article-title":"Impact of net charge, targeting ligand amount and mRNA modification on the uptake, intracellular routing and the transfection efficiency of mRNA lipopolyplexes in dendritic cells","volume":"647","author":"Delehedde","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.mtbio.2026.103334_bib223","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.tips.2009.02.005","article-title":"Siglecs as targets for therapy in immune-cell-mediated disease","volume":"30","author":"O'Reilly","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.mtbio.2026.103334_bib224","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2009-12-257386","article-title":"In vivo targeting of B-cell lymphoma with glycan ligands of CD22","volume":"115","author":"Chen","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.mtbio.2026.103334_bib225","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1021\/acschembio.1c00212","article-title":"Tolerogenic nanoparticles impacting B and T lymphocyte responses delay autoimmune arthritis in K\/BxN mice","volume":"16","author":"Srivastava","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.mtbio.2026.103334_bib226","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2025.02.047","article-title":"Using aptamers for targeted delivery of RNA therapies","author":"Driscoll","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mtbio.2026.103334_bib227","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.omtn.2018.11.011","article-title":"Genetic alphabet expansion provides versatile specificities and activities of unnatural-base DNA aptamers targeting cancer cells","volume":"14","author":"Futami","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.mtbio.2026.103334_bib228","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrd.2016.199","article-title":"Aptamers as targeted therapeutics: current potential and challenges","volume":"16","author":"Zhou","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.mtbio.2026.103334_bib229","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.biotechadv.2018.11.001","article-title":"Three decades of nucleic acid aptamer technologies: lessons learned, progress and opportunities on aptamer development","volume":"37","author":"Wang","year":"2019","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.mtbio.2026.103334_bib230","doi-asserted-by":"crossref","first-page":"eabf2400","DOI":"10.1126\/sciadv.abf2400","article-title":"Immune cell shuttle for precise delivery of nanotherapeutics for heart disease and cancer","volume":"7","author":"Huang","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.mtbio.2026.103334_bib231","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ymthe.2016.10.021","article-title":"Aptamer-targeted attenuation of IL-2 signaling in CD8+ T cells enhances antitumor immunity","volume":"25","author":"Rajagopalan","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mtbio.2026.103334_bib232","doi-asserted-by":"crossref","first-page":"18590","DOI":"10.1021\/acsami.2c20846","article-title":"Aptamer-functionalized nanovaccines: targeting in vivo DC subsets for enhanced antitumor immunity","volume":"15","author":"Zheng","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.mtbio.2026.103334_bib233","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-1-61779-921-1_7","article-title":"Therapeutic proteins, methods and protocols","volume":"899","author":"Feldwisch","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.mtbio.2026.103334_bib234","series-title":"Affibody Phage Display Selections for Lipid Nanoparticle and affibody-mediated Transient CAR T-cell Therapy","author":"Idris","year":"2022"},{"key":"10.1016\/j.mtbio.2026.103334_bib235","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1517\/17425247.2016.1121987","article-title":"Improved therapeutic activity of HER2 Affibody-targeted cisplatin liposomes in HER2-expressing breast tumor models","volume":"13","author":"Alavizadeh","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.mtbio.2026.103334_bib236","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.drudis.2008.04.013","article-title":"DARPins: a new generation of protein therapeutics","volume":"13","author":"Stumpp","year":"2008","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.mtbio.2026.103334_bib237","doi-asserted-by":"crossref","first-page":"8680","DOI":"10.3390\/ijms24108680","article-title":"Recent advances on Affibody- and DARPin-Conjugated nanomaterials in cancer therapy","volume":"24","author":"Gabriele","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mtbio.2026.103334_bib238","series-title":"IN VITRO AND IN VIVO GENE DELIVERY TO IMMUNE EFFECTOR CELLS USING NANOPARTICLES FUNCTIONALIZED WITH DESIGNED ANKYRIN REPEAT PROTEINS (DARPINS)","author":"Annika","year":"2021"},{"key":"10.1016\/j.mtbio.2026.103334_bib239","doi-asserted-by":"crossref","first-page":"6438","DOI":"10.3390\/molecules28186438","article-title":"Therapeutic antibodies in medicine","volume":"28","author":"Sharma","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.mtbio.2026.103334_bib240","doi-asserted-by":"crossref","DOI":"10.1063\/5.0158032","article-title":"Protein engineering of antibody fragments for pharmaceutical production","volume":"10","author":"Kuwahara","year":"2023","journal-title":"Appl. Phys. Rev."},{"key":"10.1016\/j.mtbio.2026.103334_bib241","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s11671-025-04200-2","article-title":"Trends in nanobody technology in industrialization","volume":"20","author":"Wu","year":"2025","journal-title":"Discov. Nano"},{"key":"10.1016\/j.mtbio.2026.103334_bib242","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3390\/medicina57111209","article-title":"Peptide-based drug delivery systems","volume":"57","author":"Berillo","year":"2021","journal-title":"Medicina"},{"key":"10.1016\/j.mtbio.2026.103334_bib243","article-title":"Exploring carbohydrates for therapeutics: a review on future directions","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"21","key":"10.1016\/j.mtbio.2026.103334_bib244","article-title":"A decade of clinical experience with DARPins in oncology and virology: a systematic review","volume":"5","author":"Stumpp","year":"2025","journal-title":"medRxiv"},{"key":"10.1016\/j.mtbio.2026.103334_bib245","doi-asserted-by":"crossref","DOI":"10.1101\/pdb.top107760","article-title":"Engineering of affibody molecules","volume":"2024","author":"St\u00e5hl","year":"2024","journal-title":"Cold Spring Harb. Protoc."},{"key":"10.1016\/j.mtbio.2026.103334_bib246","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/nat.2018.0734","article-title":"MicroRNAs enable mRNA therapeutics to selectively program cancer cells to self-destruct","volume":"28","author":"Jain","year":"2018","journal-title":"nucleic acid Ther"},{"key":"10.1016\/j.mtbio.2026.103334_bib247","doi-asserted-by":"crossref","first-page":"eadm8451","DOI":"10.1126\/scitranslmed.adm8451","article-title":"Adjuvantation of a SARS-CoV-2 mRNA vaccine with controlled tissue-specific expression of an mRNA encoding IL-12p70","volume":"16","author":"Brook","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.mtbio.2026.103334_bib248","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202401015","article-title":"Harnessing synthetic riboswitches for tunable gene regulation in mammalian cells","volume":"26","author":"Khadake","year":"2025","journal-title":"Chembiochem"},{"key":"10.1016\/j.mtbio.2026.103334_bib249","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/cbic.202000423","article-title":"Regulating CRISPR\/Cas9 function through conditional guide RNA control","volume":"22","author":"Brown","year":"2021","journal-title":"Chembiochem"},{"key":"10.1016\/j.mtbio.2026.103334_bib250","doi-asserted-by":"crossref","first-page":"12223","DOI":"10.1039\/C9CC05531B","article-title":"Control of CRISPR-Cas9 with small molecule-activated allosteric aptamer regulating sgRNAs","volume":"55","author":"Lin","year":"2019","journal-title":"Chem. Commun."},{"key":"10.1016\/j.mtbio.2026.103334_bib251","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41589-018-0186-1","article-title":"Riboregulated toehold-gated gRNA for programmable CRISPR\u2013Cas9 function","volume":"15","author":"Siu","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.mtbio.2026.103334_bib252","doi-asserted-by":"crossref","first-page":"20612","DOI":"10.1002\/anie.202009062","article-title":"Programmable live\u2010cell CRISPR imaging with toehold\u2010switch\u2010mediated strand displacement","volume":"59","author":"Hao","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.mtbio.2026.103334_bib253","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/s42003-024-06988-8","article-title":"Intelligent guide RNA: dual toehold switches for modulating luciferase in the presence of trigger RNA","volume":"7","author":"Hashemabadi","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.mtbio.2026.103334_bib254","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41587-021-01068-2","article-title":"RNA-responsive elements for eukaryotic translational control","volume":"40","author":"Zhao","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib255","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41467-024-55547-6","article-title":"Selectively expressed RNA molecules as a versatile tool for functionalized cell targeting","volume":"16","author":"Rastfeld","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103334_bib256","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/gb-2012-13-12-252","article-title":"The ADAR protein family","volume":"13","author":"Savva","year":"2012","journal-title":"Genome Biol."},{"key":"10.1016\/j.mtbio.2026.103334_bib257","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/bs.mie.2024.11.027","article-title":"CellREADR: an ADAR-based RNA sensor-actuator device","volume":"710","author":"Yang","year":"2025","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.mtbio.2026.103334_bib258","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1126\/science.adw0397","article-title":"Empower the age of smart mRNA medicine: programmable RNA sensor and molecular tools refine therapeutic payload production","volume":"388","author":"Gao","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.mtbio.2026.103334_bib259","doi-asserted-by":"crossref","first-page":"370","DOI":"10.34133\/research.0370","article-title":"Unlocking the therapeutic applicability of LNP-mRNA: chemistry, formulation, and clinical strategies","volume":"7","author":"Huang","year":"2024","journal-title":"Research"},{"key":"10.1016\/j.mtbio.2026.103334_bib260","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12929-024-01080-z","article-title":"Current landscape of mRNA technologies and delivery systems for new modality therapeutics","volume":"31","author":"Lu","year":"2024","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.mtbio.2026.103334_bib261","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.70007","article-title":"Engineering lipid nanoparticles for mRNA immunotherapy","volume":"17","author":"Zwolsman","year":"2025","journal-title":"Wiley Interdiscip. Rev., Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib262","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202409945","article-title":"Conjugation chemistry markedly impacts toxicity and biodistribution of targeted nanoparticles, mediated by complement activation","volume":"37","author":"Zaleski","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.mtbio.2026.103334_bib263","doi-asserted-by":"crossref","first-page":"255","DOI":"10.52601\/bpr.2023.230022","article-title":"Surface engineering of lipid nanoparticles: targeted nucleic acid delivery and beyond","volume":"9","author":"Lin","year":"2023","journal-title":"Biophys. Rep."},{"key":"10.1016\/j.mtbio.2026.103334_bib264","article-title":"Fabrication of active targeting lipid nanoparticles: challenges and perspectives","volume":"16","author":"Menon","year":"2022","journal-title":"Mater. Today Adv."},{"key":"10.1016\/j.mtbio.2026.103334_bib265","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1039\/D3NA00198A","article-title":"Strategies for targeted gene delivery using lipid nanoparticles and cell-derived nanovesicles","volume":"5","author":"Lee","year":"2023","journal-title":"Nanoscale Adv."},{"key":"10.1016\/j.mtbio.2026.103334_bib266","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/chem.201803174","article-title":"Bioconjugation with maleimides: a useful tool for chemical biology","volume":"25","author":"Ravasco","year":"2019","journal-title":"Chem. Eur J."},{"key":"10.1016\/j.mtbio.2026.103334_bib267","article-title":"Antigen presenting cell mimetic lipid nanoparticles for rapid mRNA CAR T cell cancer immunotherapy","volume":"36","author":"Metzloff","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.mtbio.2026.103334_bib268","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1021\/acs.nanolett.4c05186","article-title":"Peptide-functionalized lipid nanoparticles for targeted systemic mRNA delivery to the brain","volume":"25","author":"Han","year":"2025","journal-title":"Nano Lett."},{"key":"10.1016\/j.mtbio.2026.103334_bib269","article-title":"A head-to-head comparison of conjugation methods for VHHs: random maleimide-thiol coupling versus controlled click chemistry","volume":"1","author":"Moorsel","year":"2019","journal-title":"Int. J. Pharm. X"},{"key":"10.1016\/j.mtbio.2026.103334_bib270","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1021\/bc5005262","article-title":"Long-term stabilization of maleimide\u2013thiol conjugates","volume":"26","author":"Fontaine","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.mtbio.2026.103334_bib271","doi-asserted-by":"crossref","first-page":"12868","DOI":"10.1021\/la503439g","article-title":"Succinimidyl ester surface chemistry: implications of the competition between aminolysis and hydrolysis on covalent protein immobilization","volume":"30","author":"Lim","year":"2014","journal-title":"Langmuir"},{"key":"10.1016\/j.mtbio.2026.103334_bib272","doi-asserted-by":"crossref","first-page":"eadd4623","DOI":"10.1126\/sciadv.add4623","article-title":"Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates","volume":"9","author":"Herrera-Barrera","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.mtbio.2026.103334_bib273","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.3390\/pharmaceutics16111423","article-title":"Modified PEG-lipids enhance the nasal mucosal immune capacity of lipid nanoparticle mRNA vaccines","volume":"16","author":"Li","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.mtbio.2026.103334_bib274","doi-asserted-by":"crossref","first-page":"7534","DOI":"10.1039\/D3CC01082A","article-title":"A guide to functionalisation and bioconjugation strategies to surface-initiated polymer brushes","volume":"59","author":"Neri-Cruz","year":"2023","journal-title":"Chem. Commun."},{"key":"10.1016\/j.mtbio.2026.103334_bib275","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111643","article-title":"Influence of different conjugation methods for activating antibodies on polymeric nanoparticles: effects for polyclonal expansion of human CD8+ T cells","volume":"129","author":"Weller","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.mtbio.2026.103334_bib276","doi-asserted-by":"crossref","first-page":"7122","DOI":"10.1021\/acs.chemrev.0c00928","article-title":"A hitchhiker's guide to click-chemistry with nucleic acids","volume":"121","author":"Fantoni","year":"2021","journal-title":"Chem. Rev."},{"key":"10.1016\/j.mtbio.2026.103334_bib277","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1021\/acs.bioconjchem.4c00084","article-title":"Click chemistry: reaction rates and their suitability for biomedical applications","volume":"35","author":"Luu","year":"2024","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.mtbio.2026.103334_bib278","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1021\/acs.biochem.4c00699","article-title":"Click lipid nanoparticles for the delivery of mRNA to metabolically labeled cancer cells","volume":"64","author":"Tan","year":"2025","journal-title":"Biochemistry"},{"key":"10.1016\/j.mtbio.2026.103334_bib279","doi-asserted-by":"crossref","DOI":"10.1002\/biot.202300339","article-title":"A versatile method for conjugating lipid nanoparticles on T cells through combination of click chemistry and metabolic glycoengineering","volume":"19","author":"Li","year":"2024","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.mtbio.2026.103334_bib280","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101457","article-title":"Ionizable lipid nanoparticles with functionalized PEG-lipids increase retention in the tumor microenvironment","volume":"33","author":"Jester","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.mtbio.2026.103334_bib281","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3390\/nano11040888","article-title":"Hard and soft protein Corona of nanomaterials: analysis and relevance","volume":"11","author":"Garc\u00eda-\u00c1lvarez","year":"2021","journal-title":"Nanomaterials"},{"key":"10.1016\/j.mtbio.2026.103334_bib282","doi-asserted-by":"crossref","first-page":"8699","DOI":"10.1038\/s41467-025-63726-2","article-title":"Protein corona formed on lipid nanoparticles compromises delivery efficiency of mRNA cargo","volume":"16","author":"Voke","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103334_bib283","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1038\/s41467-023-39768-9","article-title":"Multiomics analysis of naturally efficacious lipid nanoparticle coronas reveals high-density lipoprotein is necessary for their function","volume":"14","author":"Liu","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103334_bib284","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jconrel.2024.07.044","article-title":"Biofluid specific protein coronas affect lipid nanoparticle behavior in vitro","volume":"373","author":"Straten","year":"2024","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103334_bib285","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/s41565-023-01455-7","article-title":"Cholesterol modulates the physiological response to nanoparticles by changing the composition of protein corona","volume":"18","author":"Tang","year":"2023","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib286","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1021\/acsnano.5c18112","article-title":"The biology of endosomal escape: strategies for enhanced delivery of therapeutics","volume":"20","author":"Chahal","year":"2026","journal-title":"ACS Nano"},{"key":"10.1016\/j.mtbio.2026.103334_bib287","article-title":"Endosomal escape of delivered mRNA from endosomal recycling tubules visualized at the nanoscale","volume":"221","author":"Paramasivam","year":"2021","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.mtbio.2026.103334_bib288","article-title":"Beyond the endosomal bottleneck: understanding the efficiency of mRNA\/LNP delivery","volume":"34","author":"Liu","year":"2024","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.mtbio.2026.103334_bib289","doi-asserted-by":"crossref","first-page":"5354","DOI":"10.1038\/s41467-025-60959-z","article-title":"Cellular and biophysical barriers to lipid nanoparticle mediated delivery of RNA to the cytosol","volume":"16","author":"Johansson","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103334_bib290","first-page":"1","article-title":"In vivo endosomal escape assay identifies mechanisms for efficient hepatic LNP delivery","author":"Jozi\u0107","year":"2026","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib291","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","article-title":"Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics","volume":"55","author":"Lee","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.mtbio.2026.103334_bib292","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2024.102163","article-title":"Anti-PEG antibodies: current situation and countermeasures","volume":"55","author":"Fu","year":"2024","journal-title":"Nano Today"},{"key":"10.1016\/j.mtbio.2026.103334_bib293","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/bjh.16254","article-title":"Acute lymphoblastic leukaemia patients treated with PEGasparaginase develop antibodies to PEG and the succinate linker","volume":"189","author":"Kloos","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.mtbio.2026.103334_bib294","doi-asserted-by":"crossref","first-page":"11804","DOI":"10.1021\/acs.analchem.6b03437","article-title":"Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population","volume":"88","author":"Yang","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/j.mtbio.2026.103334_bib295","first-page":"22","volume":"vol. 24","author":"Fang","year":"2017"},{"key":"10.1016\/j.mtbio.2026.103334_bib296","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","article-title":"Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics","volume":"55","author":"Lee","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.mtbio.2026.103334_bib297","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2024.102163","article-title":"Anti-PEG antibodies: current situation and countermeasures","volume":"55","author":"Fu","year":"2024","journal-title":"Nano Today"},{"key":"10.1016\/j.mtbio.2026.103334_bib298","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.omtm.2023.05.008","article-title":"Studying how administration route and dose regulates antibody generation against LNPs for mRNA delivery with single-particle resolution","volume":"29","author":"M\u00fcnter","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.mtbio.2026.103334_bib299","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3390\/biomedicines13020299","article-title":"Anti-drug antibody response to therapeutic antibodies and potential mitigation strategies","volume":"13","author":"Howard","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.mtbio.2026.103334_bib300","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40259-023-00641-2","article-title":"Reducing immunogenicity by design: approaches to minimize immunogenicity of monoclonal antibodies","volume":"38","author":"Harris","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.mtbio.2026.103334_bib301","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3390\/encyclopedia4010038","article-title":"Techniques for theoretical prediction of immunogenic peptides","volume":"4","author":"Friedman","year":"2024","journal-title":"Encyclopedia"},{"key":"10.1016\/j.mtbio.2026.103334_bib302","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.632687","article-title":"Immunogenicity risk profile of nanobodies","volume":"12","author":"Ackaert","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mtbio.2026.103334_bib303","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/glycob\/cwm008","article-title":"Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease","volume":"17","author":"Patten","year":"2007","journal-title":"Glycobiology"},{"key":"10.1016\/j.mtbio.2026.103334_bib304","doi-asserted-by":"crossref","first-page":"G879","DOI":"10.1152\/ajpgi.2001.280.5.G879","article-title":"In vivo recognition of mannosylated proteins by hepatic mannose receptors and mannan-binding protein","volume":"280","author":"Opanasopit","year":"2001","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.mtbio.2026.103334_bib305","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0304-4165(02)00199-X","article-title":"Serum mannan binding protein inhibits mannosylated liposome-mediated transfection to macrophages","volume":"1570","author":"Opanasopit","year":"2002","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.mtbio.2026.103334_bib306","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068810","article-title":"Potential capacity of aptamers to trigger immune activation in human blood","volume":"8","author":"Avci-Adali","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.mtbio.2026.103334_bib307","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3390\/ph11030062","article-title":"Potential inherent stimulation of the innate immune system by nucleic acid aptamers and possible corrective approaches","volume":"11","author":"Bruno","year":"2018","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.mtbio.2026.103334_bib308","first-page":"759","volume":"vol. 13","author":"Sahin","year":"2014"},{"key":"10.1016\/j.mtbio.2026.103334_bib309","first-page":"1","article-title":"Adverse effects of intravenous LNP-mediated mRNA therapy in clinical trials: a systematic review and meta-analysis","author":"Wu","year":"2025","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.mtbio.2026.103334_bib310","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1016\/j.cell.2023.07.039","article-title":"Phage-assisted evolution and protein engineering yield compact, efficient prime editors","volume":"186","author":"Doman","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.mtbio.2026.103334_bib311","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41434-024-00499-1","article-title":"Prime editing: therapeutic advances and mechanistic insights","volume":"32","author":"Murray","year":"2025","journal-title":"Gene Ther."},{"key":"10.1016\/j.mtbio.2026.103334_bib312","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1038\/s41598-024-52685-1","article-title":"A careful look at lipid nanoparticle characterization: analysis of benchmark formulations for encapsulation of RNA cargo size gradient","volume":"14","author":"Schober","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mtbio.2026.103334_bib313","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1021\/acs.molpharmaceut.2c00032","article-title":"Optimization of lipid nanoparticles for saRNA expression and cellular activation using a design-of-experiment approach","volume":"19","author":"Ly","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.mtbio.2026.103334_bib314","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41434-019-0095-2","article-title":"Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA","volume":"26","author":"Blakney","year":"2019","journal-title":"Gene Ther."},{"key":"10.1016\/j.mtbio.2026.103334_bib315","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2026.04.028","article-title":"Messenger RNA and guide RNA distributions in lipid nanoparticles impact gene-editing efficiency in vivo","author":"Truong","year":"2026","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mtbio.2026.103334_bib316","doi-asserted-by":"crossref","first-page":"9119","DOI":"10.1038\/s41467-024-53569-8","article-title":"Structuring lipid nanoparticles, DNA, and protein corona into stealth bionanoarchitectures for in vivo gene delivery","volume":"15","author":"Renzi","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103334_bib317","doi-asserted-by":"crossref","DOI":"10.3389\/fgeed.2023.1068637","article-title":"In search of an ideal template for therapeutic genome editing: a review of current developments for structure optimization","volume":"5","author":"Shakirova","year":"2023","journal-title":"Front. Genome Ed."},{"key":"10.1016\/j.mtbio.2026.103334_bib318","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.omtn.2023.04.003","article-title":"Improving cell and gene therapy safety and performance using next-generation nanoplasmid vectors","volume":"32","author":"Williams","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.mtbio.2026.103334_bib319","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41587-025-02556-5","article-title":"Safer non-viral DNA delivery using lipid nanoparticles loaded with endogenous anti-inflammatory lipids","volume":"44","author":"Patel","year":"2026","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib320","article-title":"Lipid nanoparticles for the delivery of CRISPR\/Cas9 machinery to enable site\u2010specific integration of CFTR and mutation\u2010agnostic disease rescue","volume":"36","author":"Foley","year":"2026","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.mtbio.2026.103334_bib321","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3390\/pharmaceutics14010213","article-title":"Impact of formulation conditions on lipid nanoparticle characteristics and functional delivery of CRISPR RNP for gene knock-out and correction","volume":"14","author":"Walther","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.mtbio.2026.103334_bib322","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114207","article-title":"Comparative analysis of lipid nanoparticle-mediated delivery of CRISPR-Cas9 RNP versus mRNA\/sgRNA for gene editing in vitro and in vivo","volume":"196","author":"Walther","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.mtbio.2026.103334_bib323","first-page":"1","article-title":"Lung and liver editing by lipid nanoparticle delivery of a stable CRISPR\u2013Cas9 ribonucleoprotein","author":"Chen","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib324","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.mtbio.2026.103334_bib325","article-title":"Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mtbio.2026.103334_bib326","first-page":"1","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","author":"Peng","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.mtbio.2026.103334_bib327","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2319856121","article-title":"IL7 increases targeted lipid nanoparticle\u2013mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation","volume":"121","author":"Tilsed","year":"2024","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.mtbio.2026.103334_bib328","doi-asserted-by":"crossref","first-page":"6472","DOI":"10.1038\/s41598-021-85960-6","article-title":"Metabolic changes of Interleukin-12\/15\/18-stimulated human NK cells","volume":"11","author":"Terr\u00e9n","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mtbio.2026.103334_bib329","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1006\/cimm.1996.0003","article-title":"Expression and function of low-density lipoprotein receptors in CD3\u2212CD16+CD56+Cells: effect of interleukin 2","volume":"167","author":"Sanctis","year":"1996","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.mtbio.2026.103334_bib330","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1016\/j.jcyt.2024.03.304","article-title":"Promoting long-term persistence and efficacy of car-t cells and adoptive cellular products by the restoration of their autophagy machinery","volume":"26","author":"Theinert","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.mtbio.2026.103334_bib331","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12967-024-06052-3","article-title":"From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy","volume":"23","author":"Pinto","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.mtbio.2026.103334_bib332","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41409-024-02429-6","article-title":"CAR-T cell therapy embarks on autoimmune disease","volume":"60","author":"Rampotas","year":"2025","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.mtbio.2026.103334_bib333","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12935-024-03315-3","article-title":"Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors","volume":"24","author":"Chen","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.mtbio.2026.103334_bib334","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41571-024-00959-y","article-title":"Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks","volume":"22","author":"Diorio","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.mtbio.2026.103334_bib335","doi-asserted-by":"crossref","first-page":"6983","DOI":"10.1038\/s41467-023-42672-x","article-title":"Charge-altering releasable transporters enhance mRNA delivery in vitro and exhibit in vivo tropism","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103334_bib336","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jconrel.2022.11.038","article-title":"Polymer- and lipid-based gene delivery technology for CAR T cell therapy","volume":"353","author":"Pinto","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103334_bib337","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.jcyt.2025.03.054","article-title":"Versatile lipid nanoparticle platform for efficient CRISPR-Cas9 gene editing in primary T cells and CD34+ progenitor cells and engineering cells","volume":"27","author":"Geczy","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.mtbio.2026.103334_bib338","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1166\/jbn.2019.2712","article-title":"Generation of cancer-specific cytotoxic PD-1\u2013 T cells using liposome-encapsulated CRISPR\/cas system with dendritic\/tumor fusion cells","volume":"15","author":"Lu","year":"2019","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib339","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1038\/s41467-025-60001-2","article-title":"Efficient mRNA delivery to resting T cells to reverse HIV latency","volume":"16","author":"Cevaal","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103334_bib340","series-title":"Surface-Modified Lipid Nanoparticles","author":"Zhan","year":"2024"},{"key":"10.1016\/j.mtbio.2026.103334_bib341","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","article-title":"Natural killer cell therapies","volume":"626","author":"Vivier","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.mtbio.2026.103334_bib342","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.mtbio.2026.103334_bib343","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1186\/s12951-024-02746-4","article-title":"Non-viral approaches in CAR-NK cell engineering: connecting natural killer cell biology and gene delivery","volume":"22","author":"McErlean","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib344","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13045-022-01382-5","article-title":"Natural killer cells in clinical development as non-engineered, engineered, and combination therapies","volume":"15","author":"Lamers-Kok","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.mtbio.2026.103334_bib345","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2127282","article-title":"A novel membrane-bound interleukin-2 promotes NK-92 cell persistence and anti-tumor activity","volume":"11","author":"Xiong","year":"2022","journal-title":"OncoImmunology"},{"key":"10.1016\/j.mtbio.2026.103334_bib346","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.stem.2020.05.008","article-title":"Metabolic reprograming via deletion of CISH in human iPSC-Derived NK cells promotes in vivo persistence and enhances anti-tumor activity","volume":"27","author":"Zhu","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.mtbio.2026.103334_bib347","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004244","article-title":"Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity","volume":"10","author":"Bernard","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.mtbio.2026.103334_bib348","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.2020007748","article-title":"Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells","volume":"137","author":"Daher","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.mtbio.2026.103334_bib349","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ymthe.2019.10.009","article-title":"A genetically engineered primary human natural killer cell platform for cancer immunotherapy","volume":"28","author":"Pomeroy","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mtbio.2026.103334_bib350","doi-asserted-by":"crossref","first-page":"5687","DOI":"10.1182\/blood-2018-99-116621","article-title":"Disruption of SOCS3 promotes the anti-cancer efficacy of primary NK cells","volume":"132","author":"Kararoudi","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.mtbio.2026.103334_bib351","first-page":"947","volume":"vol. 28","author":"El-Mayta","year":"2021"},{"key":"10.1016\/j.mtbio.2026.103334_bib352","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2020-142494","article-title":"CD33 targeting primary CAR-NK cells generated by CRISPR mediated gene insertion show enhanced Anti-AML activity","volume":"136","author":"Kararoudi","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.mtbio.2026.103334_bib353","first-page":"1","article-title":"Efficient non-viral immune cell engineering using circular single-stranded DNA-mediated genomic integration","author":"Xie","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib354","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122810","article-title":"Delivering mRNA to a human NK cell line, NK-92 cells, by lipid nanoparticles","volume":"636","author":"Nakamura","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.mtbio.2026.103334_bib355","volume":"vol.609","author":"Nakamura","year":"2021"},{"key":"10.1016\/j.mtbio.2026.103334_bib356","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jconrel.2023.08.014","article-title":"Lipid nanoparticle-mediated messenger RNA delivery for ex vivo engineering of natural killer cells","volume":"361","author":"Douka","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103334_bib357","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713364","article-title":"CAR-NK cells generated with mRNA-LNPs kill tumor target cells in vitro and in vivo","volume":"24","author":"Golubovskaya","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mtbio.2026.103334_bib358","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41587-019-0325-6","article-title":"Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency","volume":"38","author":"Nguyen","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib359","article-title":"Carbonate-bearing ionizable lipids for mRNA delivery to splenic NK cells","author":"Wu","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.mtbio.2026.103334_bib360","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1016\/j.ymthe.2021.09.019","article-title":"Genome edited B cells: a new frontier in immune cell therapies","volume":"29","author":"Rogers","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mtbio.2026.103334_bib361","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1182\/bloodadvances.2020003792","article-title":"Immunotherapy perspectives in the new era of B-cell editing","volume":"5","author":"Ueda","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.mtbio.2026.103334_bib362","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/s41587-024-02283-3","article-title":"B cells as drug factories","volume":"42","author":"Sheridan","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib363","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.mtbio.2026.103334_bib364","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1016\/j.ymthe.2024.06.004","article-title":"Human plasma cells engineered to secrete bispecifics drive effective in vivo leukemia killing","volume":"32","author":"Hill","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mtbio.2026.103334_bib365","volume":"vol. 11","author":"Luo","year":"2020"},{"key":"10.1016\/j.mtbio.2026.103334_bib366","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.1038\/s41467-020-19650-8","article-title":"Vaccine elicitation of HIV broadly neutralizing antibodies from engineered B cells","volume":"11","author":"Huang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103334_bib367","volume":"vol. 11","author":"Nahmad","year":"2020"},{"key":"10.1016\/j.mtbio.2026.103334_bib368","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aax0644","article-title":"B cells engineered to express pathogen-specific antibodies protect against infection","volume":"4","author":"Moffett","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.mtbio.2026.103334_bib369","first-page":"1","article-title":"Reprogramming human B cells with custom heavy-chain antibodies","author":"Rogers","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.mtbio.2026.103334_bib370","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/s41587-022-01328-9","article-title":"In vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice","volume":"40","author":"Nahmad","year":"2022","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.mtbio.2026.103334_bib371","article-title":"In vivo production of an anti-HIV antibody from primate hematopoietic cells by non-viral knock-in","volume":"5","author":"Castelli","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.mtbio.2026.103334_bib372","doi-asserted-by":"crossref","first-page":"8239","DOI":"10.3390\/ijms22158239","article-title":"Generation of recombinant primary human B lymphocytes using non-viral vectors","volume":"22","author":"Keim","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mtbio.2026.103334_bib373","first-page":"6270","volume":"vol. 11","author":"Li","year":"2018"},{"key":"10.1016\/j.mtbio.2026.103334_bib374","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201606944","article-title":"Synthesis and biological evaluation of ionizable lipid materials for the in vivo delivery of messenger RNA to B lymphocytes","volume":"29","author":"Fenton","year":"2017","journal-title":"Adv. Mater."},{"key":"10.1016\/j.mtbio.2026.103334_bib375","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113687","article-title":"Splenic B cell-targeting lipid nanoparticles for safe and effective mRNA vaccine delivery","author":"Suzuki","year":"2025","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103334_bib376","series-title":"LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS TO PRIMARY HUMAN B-CELLS","author":"Urjeet","year":"2025"},{"key":"10.1016\/j.mtbio.2026.103334_bib377","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41576-020-00298-5","article-title":"Gene therapy using haematopoietic stem and progenitor cells","volume":"22","author":"Ferrari","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.mtbio.2026.103334_bib378","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1038\/bcj.2011.35","article-title":"Further phenotypic characterization of the primitive lineage\u2212 CD34+CD38\u2212CD90+CD45RA\u2212 hematopoietic stem cell\/progenitor cell sub-population isolated from cord blood, mobilized peripheral blood and patients with chronic myelogenous leukemia","volume":"1","author":"Wisniewski","year":"2011","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.mtbio.2026.103334_bib379","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/s41467-022-28762-2","article-title":"A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for monogenic disorders","volume":"13","author":"Tucci","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103334_bib380","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-Thalassemia","volume":"384","author":"Frangoul","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mtbio.2026.103334_bib381","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/s41587-024-02517-4","article-title":"Base editing boosts hemoglobin in sickle cell disease","volume":"42","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib382","doi-asserted-by":"crossref","DOI":"10.3389\/frhem.2024.1468952","article-title":"Recent advancements in gene therapy for sickle cell disease and \u03b2-thalassemia","volume":"3","author":"Li","year":"2024","journal-title":"Front. Hematol."},{"key":"10.1016\/j.mtbio.2026.103334_bib383","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1016\/j.ymthe.2021.09.001","article-title":"Understanding and overcoming adverse consequences of genome editing on hematopoietic stem and progenitor cells","volume":"29","author":"Lee","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mtbio.2026.103334_bib384","article-title":"Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy","volume":"2","author":"Li","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.mtbio.2026.103334_bib385","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s44222-023-00056-2","article-title":"A pluripotent road to immunoengineering","volume":"1","author":"Chang","year":"2023","journal-title":"Nat. Rev. Bioeng."},{"key":"10.1016\/j.mtbio.2026.103334_bib386","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.ymthe.2024.02.026","article-title":"Stem cell-derived CAR T cells show greater persistence, trafficking, and viral control compared to ex vivo transduced CAR T cells","volume":"32","author":"Carrillo","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mtbio.2026.103334_bib387","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001975","article-title":"CBLB ablation with CRISPR\/Cas9 enhances cytotoxicity of human placental stem cell-derived NK cells for cancer immunotherapy","volume":"9","author":"Guo","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.mtbio.2026.103334_bib388","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41467-025-55873-3","article-title":"High frequency CCR5 editing in human hematopoietic stem progenitor cells protects xenograft mice from HIV infection","volume":"16","author":"Claiborne","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103334_bib389","doi-asserted-by":"crossref","first-page":"eadi1145","DOI":"10.1126\/scitranslmed.adi1145","article-title":"Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy","volume":"15","author":"Wellhausen","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.mtbio.2026.103334_bib390","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101135","article-title":"Development of a gene edited next-generation hematopoietic cell transplant to enable acute myeloid leukemia treatment by solving off-tumor toxicity","volume":"31","author":"Lydeard","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.mtbio.2026.103334_bib391","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41577-022-00698-0","article-title":"Immunological barriers to haematopoietic stem cell gene therapy","volume":"22","author":"Charlesworth","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.mtbio.2026.103334_bib392","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102423","article-title":"Restoring hematopoietic stem and progenitor cell function in Fancc \u2212\/\u2212 mice by in situ delivery of RNA lipid nanoparticles","volume":"36","author":"Banda","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"28","key":"10.1016\/j.mtbio.2026.103334_bib393","article-title":"In vivo genome editing of human hematopoietic stem cells for treatment of blood disorders by mRNA delivery","volume":"10","author":"Xu","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.mtbio.2026.103334_bib394","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/s41565-024-01680-8","article-title":"Bone-marrow-homing lipid nanoparticles for genome editing in diseased and malignant haematopoietic stem cells","volume":"19","author":"Lian","year":"2024","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib395","first-page":"1","article-title":"Lipid nanoparticle-mediated mRNA delivery to CD34+ cells in rhesus monkeys","author":"Kim","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib396","author":"Breda"},{"key":"10.1016\/j.mtbio.2026.103334_bib397","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2400783121","article-title":"In utero delivery of targeted ionizable lipid nanoparticles facilitates in vivo gene editing of hematopoietic stem cells","volume":"121","author":"Palanki","year":"2024","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.mtbio.2026.103334_bib398","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-025-02124-y","article-title":"Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets","volume":"10","author":"Guan","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.mtbio.2026.103334_bib399","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40364-024-00637-2","article-title":"CAR macrophages: a promising novel immunotherapy for solid tumors and beyond","volume":"12","author":"Lu","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.mtbio.2026.103334_bib400","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41467-024-55770-1","article-title":"Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models","volume":"16","author":"Pierini","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103334_bib401","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/s41423-024-01220-3","article-title":"Silencing of SIRP\u03b1 enhances the antitumor efficacy of CAR-M in solid tumors","volume":"21","author":"Zhang","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.mtbio.2026.103334_bib402","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1038\/s41467-025-59326-9","article-title":"CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentation","volume":"16","author":"Chen","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103334_bib403","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106427","article-title":"Sialic acid-targeted cyclodextrin-based nanoparticles deliver CSF-1R siRNA and reprogram tumour-associated macrophages for immunotherapy of prostate cancer","volume":"185","author":"Sun","year":"2023","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.mtbio.2026.103334_bib404","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/s12276-023-01068-z","article-title":"A new era of macrophage-based cell therapy","volume":"55","author":"Na","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.mtbio.2026.103334_bib405","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/s41467-024-44941-9","article-title":"Bacterial protoplast-derived nanovesicles carrying CRISPR-Cas9 tools re-educate tumor-associated macrophages for enhanced cancer immunotherapy","volume":"15","author":"Zhao","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103334_bib406","first-page":"2870","article-title":"HIF1\u03b1 epigenetically repressed macrophages via CRISPR\/Cas9-EZH2 system for enhanced cancer immunotherapy","volume":"6","author":"Dong","year":"2021","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.mtbio.2026.103334_bib407","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191692","article-title":"Efficient gene knockout in primary human and murine myeloid cells by non-viral delivery of CRISPR-Cas9","volume":"217","author":"Freund","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.mtbio.2026.103334_bib408","volume":"vol. 10","author":"Moradian","year":"2020"},{"issue":"12","key":"10.1016\/j.mtbio.2026.103334_bib409","article-title":"Targeted delivery of RNA-based therapeutics enables functional analysis of macrophage subpopulations","volume":"3","author":"Rasmussen","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.mtbio.2026.103334_bib410","doi-asserted-by":"crossref","first-page":"eads2295","DOI":"10.1126\/sciadv.ads2295","article-title":"Macrophage-targeted Mms6 mRNA-lipid nanoparticles promote locomotor functional recovery after traumatic spinal cord injury in mice","volume":"11","author":"Fu","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.mtbio.2026.103334_bib411","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1021\/acsnano.3c10109","article-title":"mRNA-Laden lipid-nanoparticle-enabled in situ CAR-macrophage engineering for the eradication of multidrug-resistant bacteria in a sepsis mouse model","volume":"18","author":"Tang","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.mtbio.2026.103334_bib412","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jconrel.2023.07.021","article-title":"Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy","volume":"360","author":"Yang","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.mtbio.2026.103334_bib413","doi-asserted-by":"crossref","first-page":"eadl5800","DOI":"10.1126\/scitranslmed.adl5800","article-title":"Macrophage-specific in vivo RNA editing promotes phagocytosis and antitumor immunity in mice","volume":"17","author":"Chen","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.mtbio.2026.103334_bib414","article-title":"Targeted macrophage CRISPR\u2010Cas13 mRNA editing in immunotherapy for tendon injury","volume":"36","author":"Wang","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.mtbio.2026.103334_bib415","article-title":"The instructive role of dendritic cells on T-cell responses","volume":"4","author":"Sallusto","year":"2002","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.mtbio.2026.103334_bib416","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.immuni.2013.07.004","article-title":"Dendritic-cell-based therapeutic cancer vaccines","volume":"39","author":"Palucka","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.mtbio.2026.103334_bib417","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/CJI.0b013e31821dcb31","article-title":"Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma","volume":"34","author":"Wilgenhof","year":"2011","journal-title":"J. Immunother."},{"key":"10.1016\/j.mtbio.2026.103334_bib418","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mtbio.2026.103334_bib419","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s43018-020-0075-x","article-title":"PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer","volume":"1","author":"Oh","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.mtbio.2026.103334_bib420","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/mt.2011.57","article-title":"Engineering dendritic cells to enhance cancer immunotherapy","volume":"19","author":"Boudreau","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.mtbio.2026.103334_bib421","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12964-024-01641-7","article-title":"Emerging strategies for treating autoimmune disease with genetically modified dendritic cells","volume":"22","author":"Ma","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.mtbio.2026.103334_bib422","doi-asserted-by":"crossref","first-page":"4729","DOI":"10.1038\/s41467-023-40519-z","article-title":"Cas9-mediated knockout of Ndrg2 enhances the regenerative potential of dendritic cells for wound healing","volume":"14","author":"Henn","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103334_bib423","doi-asserted-by":"crossref","DOI":"10.1038\/srep29891","article-title":"An efficient method for gene silencing in human primary plasmacytoid dendritic cells: silencing of the TLR7\/IRF-7 pathway as a proof of concept","volume":"6","author":"Smith","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mtbio.2026.103334_bib424","first-page":"9815","volume":"vol. 12","author":"Jeught","year":"2018"},{"key":"10.1016\/j.mtbio.2026.103334_bib425","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202419182","article-title":"Screening natural cholesterol analogs to assemble self\u2010adjuvant lipid nanoparticles for antigens tagging guided therapeutic tumor vaccine","author":"Liang","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.mtbio.2026.103334_bib426","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119302","article-title":"In situ repurposing of dendritic cells with CRISPR\/Cas9-based nanomedicine to induce transplant tolerance","volume":"217","author":"Zhang","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.mtbio.2026.103334_bib427","doi-asserted-by":"crossref","first-page":"9990","DOI":"10.1038\/s41467-024-54265-3","article-title":"Rational strategies for improving the efficiency of design and discovery of nanomedicines","volume":"15","author":"Shan","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mtbio.2026.103334_bib428","doi-asserted-by":"crossref","first-page":"4822","DOI":"10.1021\/acs.nanolett.2c01133","article-title":"Universal barcoding predicts in vivo ApoE-Independent lipid nanoparticle delivery","volume":"22","author":"Sanchez","year":"2022","journal-title":"Nano Lett."},{"key":"10.1016\/j.mtbio.2026.103334_bib429","doi-asserted-by":"crossref","first-page":"eabm5551","DOI":"10.1126\/science.abm5551","article-title":"Massively parallel pooled screening reveals genomic determinants of nanoparticle delivery","volume":"377","author":"Boehnke","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.mtbio.2026.103334_bib430","doi-asserted-by":"crossref","first-page":"10492","DOI":"10.1073\/pnas.1919755117","article-title":"Machine learning predicts the functional composition of the protein corona and the cellular recognition of nanoparticles","volume":"117","author":"Ban","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.mtbio.2026.103334_bib431","doi-asserted-by":"crossref","first-page":"39736","DOI":"10.1021\/acsami.2c06627","article-title":"Microfluidic manufacturing of liposomes: development and optimization by design of experiment and machine learning","volume":"14","author":"Rebollo","year":"2022","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.mtbio.2026.103334_bib432","article-title":"Advancing cellular\u2010specific delivery: machine learning insights into lipid nanoparticles design and cellular tropism","author":"Hanafy","year":"2025","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.mtbio.2026.103334_bib433","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/s41563-024-01867-3","article-title":"Accelerating ionizable lipid discovery for mRNA delivery using machine learning and combinatorial chemistry","volume":"23","author":"Li","year":"2024","journal-title":"Nat. Mater."},{"key":"10.1016\/j.mtbio.2026.103334_bib434","first-page":"1","article-title":"Artificial intelligence-guided design of lipid nanoparticles for pulmonary gene therapy","author":"Witten","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib435","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1038\/s41467-024-50619-z","article-title":"AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery","volume":"15","author":"Xu","year":"2024","journal-title":"Nat. Commun."},{"issue":"14","key":"10.1016\/j.mtbio.2026.103334_bib436","article-title":"LUMI-lab: a foundation model-driven autonomous platform enabling discovery of new ionizable lipid designs for mRNA delivery","volume":"2","author":"Cui","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.mtbio.2026.103334_bib437","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1335901","article-title":"Advancing genome editing with artificial intelligence: opportunities, challenges, and future directions","volume":"11","author":"Dixit","year":"2024","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib438","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/s41587-019-0203-2","article-title":"Large dataset enables prediction of repair after CRISPR\u2013Cas9 editing in primary T cells","volume":"37","author":"Leenay","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib439","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41587-024-02268-2","article-title":"Machine learning prediction of prime editing efficiency across diverse chromatin contexts","volume":"43","author":"Mathis","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mtbio.2026.103334_bib440","first-page":"1","article-title":"CRISPR-GPT for agentic automation of gene-editing experiments","author":"Qu","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.mtbio.2026.103334_bib441","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/d41573-023-00002-2","article-title":"The landscape for lipid-nanoparticle-based genomic medicines","volume":"22","author":"Verma","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.mtbio.2026.103334_bib442","doi-asserted-by":"crossref","DOI":"10.1038\/d41573-024-00150-z","article-title":"In vivo CAR T cells move into clinical trials","author":"Mullard","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.mtbio.2026.103334_bib443","series-title":"Cowen Equity Research - Trials and Triumphs of Genomic Medicines: Gene Therapy and Gene Editing Landscape Update","author":"Thome","year":"2023"},{"key":"10.1016\/j.mtbio.2026.103334_bib444","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1080\/01621459.1976.10480949","article-title":"Science and statistics","volume":"71","author":"Box","year":"1976","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.mtbio.2026.103334_bib445","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1016\/j.vaccine.2017.03.099","article-title":"The in vitro MIMIC\u00ae platform reflects age-associated changes in immunological responses after influenza vaccination","volume":"35","author":"Dauner","year":"2017","journal-title":"Vaccine"}],"container-title":["Materials Today Bio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S259000642600579X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S259000642600579X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:09:59Z","timestamp":1787026199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S259000642600579X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":445,"alternative-id":["S259000642600579X"],"URL":"https:\/\/doi.org\/10.1016\/j.mtbio.2026.103334","relation":{},"ISSN":["2590-0064"],"issn-type":[{"value":"2590-0064","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delivering the future of immunotherapy: A state-of-the-art review of gene editing in immune cells with lipid nanoparticles","name":"articletitle","label":"Article Title"},{"value":"Materials Today Bio","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mtbio.2026.103334","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103334"}}